Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 406-750-9 | CAS number: 129757-67-1 TINUVIN 123
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- other: assessment
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Because of limited data (which are provided by ECHA) it is difficult to make a full toxicokinetic assessment.
Data source
Reference
- Reference Type:
- other: Body responsible for the test
- Title:
- Unnamed
- Year:
- 1 991
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: ECHA Guidance on information requirements and chemical safety assessment, Chapter R.7c: Endpoint specific guidance, R.7.12 Guidance on Toxicokinetics
- Deviations:
- not specified
- GLP compliance:
- no
Test material
- Reference substance name:
- Reaction mass of bis[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl] decanedioate and 1,1'-bis[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl]10,10'-{octane-1,8-diylbis[oxy(2,2,6,6-tetramethylpiperidine-1,4-diyl)]}
- IUPAC Name:
- Reaction mass of bis[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl] decanedioate and 1,1'-bis[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl]10,10'-{octane-1,8-diylbis[oxy(2,2,6,6-tetramethylpiperidine-1,4-diyl)]}
- Reference substance name:
- A mixture of: bis(2,2,6,6-tetramethyl-1-octyloxypiperidin-4-yl)-1,10-decanedioate; 1,8-bis[(2,2,6,6-tetramethyl-4-((2,2,6,6-tetramethyl-1-octyloxypiperidin-4-yl)-decan-1,10-dioyl)piperidin-1-yl)oxy]octane
- EC Number:
- 406-750-9
- EC Name:
- A mixture of: bis(2,2,6,6-tetramethyl-1-octyloxypiperidin-4-yl)-1,10-decanedioate; 1,8-bis[(2,2,6,6-tetramethyl-4-((2,2,6,6-tetramethyl-1-octyloxypiperidin-4-yl)-decan-1,10-dioyl)piperidin-1-yl)oxy]octane
- Cas Number:
- 129757-67-1
- Molecular formula:
- Constituent 1: C44H84N2O6 Constituent 2 : C80H150N4O12
- IUPAC Name:
- 2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl 2,2,6,6-tetramethyl-1-{[8-({2,2,6,6-tetramethyl-4-[(10-oxo-10-{[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl]oxy}decanoyl)oxy]piperidin-1-yl}oxy)octyl]oxy}piperidin-4-yl decanedioate; 2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl 2,2,6,6-tetramethyl-4-{[8-({2,2,6,6-tetramethyl-1-[(10-oxo-10-{[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl]oxy}decanoyl)oxy]piperidin-4-yl}oxy)octyl]oxy}piperidin-1-yl decanedioate; bis[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl] decanedioate
- Reference substance name:
- Reaction mass of bis[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl] decanedioate and 1,1'-bis[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl]10,10'-{octane-1,8-diylbis[oxy(2,2,6,6-tetramethylpiperidine-1,4-diyl)]}
- IUPAC Name:
- Reaction mass of bis[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl] decanedioate and 1,1'-bis[2,2,6,6-tetramethyl-1-(octyloxy)piperidin-4-yl]10,10'-{octane-1,8-diylbis[oxy(2,2,6,6-tetramethylpiperidine-1,4-diyl)]}
Constituent 1
Constituent 2
Constituent 3
Administration / exposure
- Route of administration:
- oral: unspecified
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Oral/GI absorption: With a high molecular weight (Constituent 1: 737.15 g/mol; Constituent 2 : 1360.07 g/mol), high log P value ( log Pow >10) and very low water solubility (< 6mg/L) , substance is considered to not have oral/GI absorption. The oral toxicity data showing the LD50 > 2000 mg/kg bw/day indicates that no signs of systemic toxicity is present. It is to be expected that the oral bio-availability and the systemic exposure of substance will be very low.
Respiratory absorption - Inhalation: As substance is not soluble in water, has higher log P value, has low volatility, has a low vapour pressure and its viscosity is such that it is unlikely to form aerosol mists in use, it is expected that this chemical has no potential to be inhaled. Inhalation is not a significant route of exposure during use of substance.
Dermal absorption: With low water solubility and high molecular weight, dermal absorption of substance is anticipated to be very low. As Log P value is above 6, the rate of transfer between the stratum corneum and the epidermis will be slow and will limit absorption across the skin. Uptake into the stratum corneum itself may be slow. - Details on distribution in tissues:
- 28-day oral toxicity study recorded as follow: No premature mortalities occurred. The body-weight gain was not impaired as a result of the treatment. Prolognation of the prothrombin time, which however, was reversible in the animals from the recovery group, was observed among the males from the highest-dose group. Clinico-chemicals findings, organ weights and the macroscopic investigation did not reveal any substance-related changes. The histological examination revealed an increase in the extramedullar haematopoietic activity in the liver among the male animals from the high-dose group. No further substance-related changes (including neurological findings) were determined.
In 90-day oral toxicity study there was no macroscopic pathology and no histopathological finding after 13 weeks that was attributed to treatment. Microscopic examination indicated an increased incidence of inflammatory changes in the lungs of females give 1000 mg/kg/day. These were shown to be fully reversible. Also liver weight values were slightly high after 13 weeks in males that received 150 or 1000 mg/kg/day. This change showed full recovery.
It is expected that substance has a lower volume of distribution in the human body owing to its high molecular weight, which has less capability of distributing in tissues in body. Accumulation in fat or in other tissues is unlikely.
- Details on excretion:
- With a high molecular weight and low water solubility, substance may be excreted via bile. The excretion of compounds via bile is highly influenced by hepatic function as metabolites formed in the liver may be excreted directly into the bile without entering the bloodstream. Additionally, blood flow as such is a determining factor. Little is known about the determinants of biliary excretion in humans.
Metabolite characterisation studies
- Metabolites identified:
- not measured
- Details on metabolites:
- In view of its hydrophobicity, high molecular weight, high log P value, low volatility, absorption of CHIGUARD 101 is considered negligible. In the case absorption occurs, substance will be extensively metabolised in the liver and rapidly excreted via bile. Accumulation in the body during prolonged exposure will be very low.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
Based on the expected kinetic behaviour in the body, substance will hardly be absorbed after oral administration, mainly because of its hydrophobicity and higher molecule weight. Absorption dermal and inhalation are anticipated to be low thanks to low water solubility and high lop P value. If absorption occurs, substance will be extensively metabolised in the liver and excreted via bile. Substance is predicted to have no bioaccumulation potential.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.